The data underlying this study is from the Lumbar Stenosis Outcome Study (LSOS) and contain sensitive patient information. Interested researchers may obtain the data through formal application to the Horten Centre Foundation (<info@evimed.ch>) upon publication.

Introduction {#sec005}
============

Decompression surgery is a treatment option for patients with lumbar spinal stenosis. Surgical treatment is recommended for patients with moderate or severe clinical manifestations and no meaningful improvement following conservative treatment, such as physiotherapy and/or epidural steroid injections. Surveys among surgeons using standardized clinical cases revealed a lack of consensus among clinical experts on the indications for surgery \[[@pone.0207126.ref001]\], and the wide variation in surgical rates among hospital referral regions in the USA may be explained by this lack of consensus \[[@pone.0207126.ref002]\].

There is broad agreement that decompressive surgery offers an advantage for about two thirds of patients within the first four years after surgery compared to non-surgical treatment \[[@pone.0207126.ref003]--[@pone.0207126.ref006]\], while one third of patients report no meaningful improvement after surgery \[[@pone.0207126.ref004], [@pone.0207126.ref005]\]. This difference in outcome declines between surgical and non-surgical treatment five to ten years after surgery \[[@pone.0207126.ref007]--[@pone.0207126.ref009]\]. A tool for identifying patients with a high probability of post-surgical improvement would be valuable for patients and physicians in decision-making regarding surgery, and could reduce the rate of unnecessary operations.

The aim of this study was to develop a PPF for estimating the likelihood of post-surgical improvement in patients with lumbar spinal stenosis at one year follow-up, conditional on a set of prognostic indicators measured at baseline.

Materials and methods {#sec006}
=====================

The Lumbar Stenosis Outcome Study (LSOS) is a prospective cohort study investigating the effectiveness of various treatment options in patients with symptomatic lumbar spinal stenosis \[[@pone.0207126.ref010]\]. Participation in the study had no influence on the treatment of the patients, all treatment decisions were left to the patient and physician. 841 patients were recruited from December 2010 to December 2015, and were followed-up for three years.

The present study is reported according to STROBE (Statement for reporting cohort studies) guidelines \[[@pone.0207126.ref011]\] and TRIPOD (Statement for studies reporting clinical prediction models) guidelines \[[@pone.0207126.ref012]\] ([S1](#pone.0207126.s003){ref-type="supplementary-material"} and [S2 Files](#pone.0207126.s004){ref-type="supplementary-material"}).

Inclusion and exclusion criteria {#sec007}
--------------------------------

The following characteristics were required for study eligibility: age ≥50 years, uni- or bilateral neurogenic claudication, verified stenosis of the lumbar spinal canal determined by magnetic resonance imaging (MRI), life expectancy ≥1 year, ability to give informed consent, availability for follow-up, and ability to complete questionnaires in the German language. We excluded patients with cauda equina syndrome requiring urgent surgery, current fracture, infection, significant deformity (\>15° lumbar scoliosis) of the lumbar spine, current enrollment in another spine-related treatment study, and clinically relevant peripheral arterial disease (as confirmed by a vascular specialist in patients without palpable lower limb pulse).

Eligibility criteria for inclusion in the analysis {#sec008}
--------------------------------------------------

All patients who underwent surgery within six months of enrollment and with 12 months of follow-up data were included in the analysis.

Surgical procedures and radiological classification {#sec009}
---------------------------------------------------

The surgery consisted of a standard open posterior lumbar laminotomy with or without instrumentation of the affected level(s). The surgeon's discretion determined the decision to proceed with a laminotomy using unilateral technique, to decompress the contralateral recess, or to take a midline approach with bilateral laminotomy. Fusion surgery included implantation of pedicle screws with rods, plus intersomatic fusion and cage(s) at the affected level(s), in addition to decompression surgery. Additional fusion, single or multi-level decompression, or the use of an operating microscope was based on the surgeon's discretion. The procedures were done or supervised by senior neuro- or orthopedic surgeons with more than ten years of experience after board-certification, and each patient's MRI was independently evaluated by two senior radiologists.

Data collection and follow-up {#sec010}
-----------------------------

Baseline data was taken from interviews and recorded by a study coordinator. All other questionnaires were self-administered by the patients themselves. Data were collected at baseline and after 12 months.

Outcome measures {#sec011}
----------------

*Spinal Stenosis Measure (SSM)*: The SSM is an instrument specifically developed and validated for spinal stenosis patients by Stucki and colleagues \[[@pone.0207126.ref013]\], and both measures symptom severity and quantifies disability in patients with lumbar spinal stenosis. The SSM is recommended by the North American Spine Society (NASS) and is used in many different studies of lumbar spinal stenosis \[[@pone.0207126.ref014]--[@pone.0207126.ref017]\]. Scores range from 1--5 and 1--4 (best-worst) for SSM symptoms score and SSM function score. A minimal clinically important difference (MCID) in SSM symptoms score is defined by an improvement of 0.48 points from baseline to 12 months, and an improvement of 0.52 defines an MCID in SSM function score \[[@pone.0207126.ref018]\].

Development of a PPF and choice of prognostic indicators {#sec012}
--------------------------------------------------------

A PPF derives the probability of a future event based on a set of prognostic indicators defined at a specified point in time \[[@pone.0207126.ref019]\]. In this application, the future event was MCID one year after baseline in SSM symptoms score or SSM function score. We studied the literature to generate a list of prognostic indicators \[[@pone.0207126.ref020]--[@pone.0207126.ref023]\]. The dichotomous and continuous parameters measured at baseline and available in the LSOS database were included in the PROCESS (PostopeRative OutComE Spinal Stenosis) PPF. The list of prognostic indicators is summarized in [Table 1](#pone.0207126.t001){ref-type="table"}.

10.1371/journal.pone.0207126.t001

###### List of 21 prognostic indicators used in the prognostic probability function for meaningful clinically important difference (MCID) in SSM symptoms score and SSM function score one year after baseline.

![](pone.0207126.t001){#pone.0207126.t001g}

  Prognostic indicator                                         
  ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------
  *Dichotomous*                                                *Unfavorable*
  Age                                                          ≥75 years \[[@pone.0207126.ref021]\]
  Gender                                                       female
  BMI                                                          ≥30 kg/m^2^ \[[@pone.0207126.ref024]\]
  Current smoker                                               yes
  Civil status                                                 living alone, or single/divorced/widowed and living in a nursing/residential home
  Formal education                                             compulsory school only
  Coxarthrosis or gonarthrosis                                 yes
  Coronary heart disease or heart insufficiency                yes
  Asthma or COPD                                               yes
  Parkinson's disease or peripheral neuropathy                 yes
  Walking ability                                              being able to walk only up to 200 m
  Low back pain                                                yes
  Duration of symptoms                                         ≥6 months \[[@pone.0207126.ref025]\]
  Preoperative analgesic use within 3 months before baseline   yes
  Previous lumbar surgery                                      yes
  Number of decompressed levels                                \>1 level
  Radiological parameters                                      Antero-posterior diameter of dural sac (APD) \>6 mm or cross sectional area \>70 mm^2^ \[[@pone.0207126.ref022]\]
  Depression (on HADS depression scale)                        ≥8 points \[[@pone.0207126.ref026]\]
  *Continuous*                                                 *Range*
  Quality of life (EQ5D-3L scale)                              0 (worst)-- 100 (best)
  Baseline SSM symptoms score                                  1 (best)-- 5 (worst)
  Baseline SSM function score                                  1 (best)-- 4 (worst)

BMI = body mass index; COPD = chronic obstructive pulmonary disease; HADS = Hospital Anxiety and Depression Scale; SSM = Spinal Stenosis Measure

Patient scenarios {#sec013}
-----------------

The PPF's usability in terms of pain and disability was also assessed by characterizing two scenarios, one with a very favorable constellation of prognostic indicators, and the second with a disadvantageous constellation of prognostic indicators. We calculated the estimated probabilities of MCID in these two scenarios.

### Scenario 1 (favorable) {#sec014}

Male patient, all favorable prognostic indicators present ([Table 1](#pone.0207126.t001){ref-type="table"}), age \<75 years, BMI \<30 kg/m^2^, non-smoking, not living alone or single/divorced/widowed and living in a nursing/residential home, no low education, no cox- or gonarthrosis, coronary heart disease or heart insufficiency, no asthma or chronic obstructive pulmonary disease (COPD), no Parkinson's disease or peripheral neuropathy, able to walk more than 200 m, no low back pain, duration of symptoms \<6 months, analgesic use within 3 months before baseline, no previous lumbar surgery, surgery on one single lumbar spinal level, narrowing of the cross sectional area (≤70 mm^2^) or the diameter of the dural sac (≤6 mm), no depression, average quality of life score of 50 points, baseline SSM symptoms and function scores both 3.5.

### Scenario 2 (unfavorable) {#sec015}

Female patient, all favorable prognostic indicators absent ([Table 1](#pone.0207126.t001){ref-type="table"}), average quality of life score of 50, baseline SSM symptoms and function scores both 2.

Statistical methods {#sec016}
-------------------

Thorough development and validation of a PPF is important \[[@pone.0207126.ref027]\]. For that reason, patients were randomly split once into a *derivation subsample* (2/3 of the patients) for development of the PPF and a *validation subsample* (1/3 of the patients) for validation of the function, in order to determine the validity of results for new patients \[[@pone.0207126.ref028]\]. Descriptive statistics included median and interquartile ranges for continuous variables, and counts and percentages of total for categorical variables. Corresponding Wilcoxon and chi-squared tests were used to compare the two subsamples.

There was missing data for some of the patients for some of the prognostic indicators. These were filled using 10-fold multiple imputation based on chained equations \[[@pone.0207126.ref029]\], retaining the information about the derivation and validation subsamples.

The two binary outcome variables, MCID in SSM symptoms and SSM function were addressed with logistic regression models fitted to each outcome in each of the ten imputed derivation subsamples including all 21 prognostic indicators.

PPF models with a large number of prognostic indicators tend to describe optimally the data under study, but predictions for *new* subjects will perform less well. To address this phenomenon, called overfitting, the regression coefficients of the PPF can be shrinked towards zero by multiplying with a global shrinkage factor. E.g., a coefficient of 0.8 becomes 0.72 (= 0.8\*0.9) if the shrinkage factor was 0.9. We derived a global shrinkage factor for the estimated regression coefficients using the *dfbeta*-method \[[@pone.0207126.ref030]\]. A global shrinkage factor for the model addressing MCID in SSM symptoms and a global shrinkage factor for MCID in SSM function was calculated in each of the ten imputed derivation subsamples and then averaged, resulting in one global shrinkage factor for each outcome.

Pooled regression coefficients were calculated from the ten derivation subsamples following Rubin's rule \[[@pone.0207126.ref031]\], and the two global shrinkage factors were applied. Original and shrunken regression coefficients are summarized as odds ratios with 95% confidence intervals (CI). The pooled and shrunken regression coefficients were applied to each of the ten multiply imputed validation subsamples, resulting in predictions of the probability for MCID in SSM symptoms and SSM function scores.

After the derivation of a PPF, one would like to know how well the predicted probability for MCID (continuous between 0 and 1) corresponds to the actual observed MCID-status (0 or 1) in SSM symptoms and SSM function. This can be measured with the discriminative ability of the PPF, as well as with its calibration. A **r**eceiver **o**perating **c**haracteristic (ROC) plot displays the true positive rate against the false positive rate for consecutive cut-offs for the predicted probability. The **a**rea **u**nder this ROC **c**urve (AUC) with 95% CI is calculated to assess the discriminative ability of the PPF. Calibration is another important property of a probability function, and it measures the agreement between observed outcomes and predictions. We used calibration plots, for 10-fold imputed derivation and validation subsamples.

All analyses were conducted using R for Windows \[[@pone.0207126.ref032]\], using the packages *dplyr*, *MASS*, *mice*, *mitools*, *openxlsx*, *PresenceAbsence*, *pROC*, *rms*, *rpart*, *shrink*, and *tableone*. Our work was conducted following the concept of reproducible research and the R-code is available upon request \[[@pone.0207126.ref033]\].

Sample size {#sec017}
-----------

The sample size was calculated for the development of a PPF for patients undergoing spine surgery, one year after surgery \[[@pone.0207126.ref010]\]. For sample size calculation, we anticipated that 60% of the included 841 patients (= 505 patients) with verified diagnosis would undergo surgery. Actually, 543 patients underwent surgery during the follow-up, 498 of these within the first six months after baseline and 452 of these had a follow-up of at least 12 months.

We anticipated that two thirds of the patients would show a clinically relevant improvement one year after surgery. Based these assumptions, the number of prognostic indicators in the logistic regression model in the derivation set may be up to 20 following the rule of 10 outcome events per predictor variable (EPV). According to Vittinghoff and McCulloch \[[@pone.0207126.ref034]\], this rule can be relaxed to 5 to 9 EPVs allowing for up to 22 prognostic indicators if 9 EPVs are taken as threshold.

Ethical approval {#sec018}
----------------

This multi-centre cohort study was conducted in compliance with all international laws and regulations as well as any applicable guidelines. Written informed consent to participate in the study has been obtained from participants. The study was approved by the independent Ethics Committee of the Canton Zurich (KEK-ZH-NR: 2010-0395/0).

Results {#sec019}
=======

Patient characteristics {#sec020}
-----------------------

Four hundred and fifty-two patients who received surgery for lumbar spinal stenosis within six months of baseline had 12-month follow-up data ([Fig 1](#pone.0207126.g001){ref-type="fig"}). 300 were randomly selected for the derivation subsample, and the remaining 152 patients were allocated to the validation subsample. 141 patients in the derivation subsample (47%) were 75 years or older, while 73 (48%) of patients in the validation subsample were in the same age range. 51% and 52%, respectively, were female. Details for all prognostic indicators are shown in [Table 2](#pone.0207126.t002){ref-type="table"}. There were no differences between the subsamples across all variables.

![Patient flow chart.](pone.0207126.g001){#pone.0207126.g001}

10.1371/journal.pone.0207126.t002

###### Preoperative baseline characteristics.
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  ----------------------------------------------------------------------------------------------------------------------------------------------
                                                                                           Derivation\           Validation\           p-value
                                                                                           data set              data set              
  ---------------------------------------------------------------------------------------- --------------------- --------------------- ---------
                                                                                           N = 300               N = 152               

  Age ≥75 years, No. (%)                                                                   141 (47.0)            73 (48.0)             0.915

  Female gender, No. (%)                                                                   152 (50.7)            79 (52.0)             0.870

  BMI ≥30 kg/m^2^, No. (%)                                                                 83 (27.7)             47 (30.9)             0.540

  Current smoker, No. (%)                                                                  50 (16.7)             24 (15.9)             0.929

  Living alone, or single/divorced/widowed and living in nursing home, No. (%)             95 (31.7)             56 (36.8)             0.319

  Compulsory school only, No. (%)                                                          70 (23.5)             45 (29.6)             0.196

  Coxarthrosis or gonarthrosis, No. (%)                                                    105 (38.0)            54 (36.7)             0.873

  Coronary heart disease or heart insufficiency, No. (%)                                   19 (6.9)              10 (6.8)              1

  Asthma or COPD, No. (%)                                                                  28 (10.0)             19 (12.8)             0.465

  Parkinson's disease or peripheral neuropathy, No. (%)                                    7 (2.5)               6 (4.1)               0.552

  Being able to walk only up to 200m, No. (%)                                              209 (69.9)            99 (65.1)             0.357

  Low back pain, No. (%)                                                                   263 (88.0)            133 (88.1)            1

  Duration of symptoms ≥6 months, No. (%)                                                  182 (61.1)            87 (58.0)             0.600

  Preoperative analgesic use within 3 months before baseline, No. (%)                      242 (80.9)            117 (78.5)            0.633

  Previous lumbar surgery, No. (%)                                                         27 (9.0)              22 (14.5)             0.108

  More than one decompressed level, No. (%)                                                181 (60.5)            82 (55.8)             0.392

  Diameter of the dural sac (APD) \>6 mm or cross sectional area \>70 mm^2^ (%), No. (%)   52 (17.3)             34 (22.4)             0.245

  Depression on HADS scale ≥8, No. (%)                                                     56 (18.7)             26 (17.2)             0.793

  Quality of life on EQ5D actual health status, median \[IQR\]                             64.0 \[40.0, 80.0\]   63.5 \[40.0, 80.0\]   0.818

  Baseline SSM symptoms score, median \[IQR\]                                              3.1 \[2.7, 3.6\]      3.1 \[2.9, 3.5\]      0.912

  Baseline SSM function score, median \[IQR\]                                              2.2 \[1.8, 2.8\]      2.2 \[1.8, 2.8\]      0.808
  ----------------------------------------------------------------------------------------------------------------------------------------------

BMI = body mass index; COPD = chronic obstructive pulmonary disease; HADS = Hospital Anxiety and Depression Scale; SSM = Spinal Stenosis Measure

MCID in SSM symptoms and SSM function scores {#sec021}
--------------------------------------------

73% of the patients in the derivation subsample and 70% of patients in the validation subsample reached an MCID in SSM symptoms score after surgery. The percentages for MCID in SSM function score were 68% and 63%, respectively.

Intra- and postoperative complications {#sec022}
--------------------------------------

Eighteen (6.0%) patients of the derivation subsample suffered an injury of the dura during surgery, the corresponding numbers were 9 (5.9%) in the validation subsample. No patient in the derivation subsample and three patients (2.0%) in the validation subsample experienced epidural venous bleeding.

In the derivation subsample, 5 (1.7%) patients had a wound infection, other complications (e.g., urosepsis, hemorrhage, wound healing deficit) were experienced by 25 (8.3%) patients. In the validation subsample, no wound infections were observed, and 15 (9.9%) patients had other complications. Twenty-two (7.3%) patients had a reoperation in the derivation subsample and 15 (9.9%) patients in the validation subsample.

Multiple imputation and shrinkage factors {#sec023}
-----------------------------------------

There were missing values for 18 of the prognostic indicators. The percentage of missing values varied between 0.2% in walking ability, and 6.4% for the coxarthrosis/gonarthrosis variable. Ten-fold multiple imputation was applied.

The continuous prognostic indicators baseline SSM symptoms score and SSM function score, and EQ-5D actual health status were entered in a linear as well as in a quadratic fashion and the residual plot was in favor of the linear effect for all three of them.

The resulting average global shrinkage factors were 0.47 for MCID in SSM symptoms score and 0.60 for MCID in SSM function score.

Pooled regression coefficients expressed as log odds ratios and 95% CIs are summarized in [Table 3](#pone.0207126.t003){ref-type="table"} (MCID in SSM symptoms score as outcome) and [Table 4](#pone.0207126.t004){ref-type="table"} (MCID in SSM function score as outcome). The shrinked regression coefficients are also displayed for each outcome. These were the final coefficients, and were used for calculating the probability of MCID in SSM symptoms score and SSM function score following surgery.

10.1371/journal.pone.0207126.t003

###### PROCESS: Estimated coefficients and their 95% confidence intervals, p-values, and shrinked coefficients for the SSM symptoms score.

The shrinkage factor was 0.47.
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  MCID in SSM symptoms                                                                     Coefficients = log odds ratios   Lower bound of 95% CI   Upper bound of 95% CI   p-value   Shrinked coefficients
  ---------------------------------------------------------------------------------------- -------------------------------- ----------------------- ----------------------- --------- -----------------------
  (Intercept)                                                                              -1.212                           -3.878                  1.455                   0.372     -0.565
  Age                                                                                      -0.460                           -1.090                  0.171                   0.152     -0.214
  Gender                                                                                   0.108                            -0.568                  0.785                   0.753     0.050
  Body mass index                                                                          -0.443                           -1.118                  0.232                   0.197     -0.207
  Current smoker                                                                           -0.021                           -0.853                  0.811                   0.960     -0.010
  Civil status                                                                             -0.178                           -0.874                  0.519                   0.616     -0.083
  Formal education                                                                         -0.232                           -0.924                  0.460                   0.510     -0.108
  Coxarthrosis or gonarthrosis                                                             -0.399                           -1.041                  0.243                   0.221     -0.186
  Coronary heart disease or heart insufficiency                                            -1.221                           -2.348                  -0.093                  0.034     -0.569
  Asthma or COPD                                                                           0.612                            -0.609                  1.833                   0.324     0.285
  Parkinson's disease or peripheral neuropathy                                             -1.218                           -3.115                  0.679                   0.206     -0.568
  Walking ability                                                                          -0.189                           -0.939                  0.561                   0.621     -0.088
  Low back pain                                                                            -0.439                           -1.405                  0.528                   0.372     -0.205
  Duration of symptoms                                                                     0.004                            -0.618                  0.626                   0.990     0.002
  Preoperative analgesic use within 3 months before baseline                               -0.070                           -0.864                  0.724                   0.862     -0.033
  Previous lumbar surgery                                                                  0.050                            -0.958                  1.057                   0.923     0.023
  Number of decompressed levels                                                            -0.269                           -0.882                  0.344                   0.389     -0.125
  Antero-posterior diameter of dural sac (APD) \>6 mm or cross sectional area \>70 mm^2^   -0.694                           -1.421                  0.032                   0.061     -0.324
  Depression (on HADS depression scale)                                                    -1.091                           -1.872                  -0.311                  0.006     -0.509
  Quality of life (EQ5D-3L scale)                                                          0.001                            -0.013                  0.015                   0.882     0
  Baseline SSM symptoms score                                                              1.396                            0.761                   2.032                   \<0.001   0.652
  Baseline SSM function score                                                              -0.174                           -0.808                  0.460                   0.589     -0.081

CI = confidence interval; COPD = chronic obstructive pulmonary disease; HADS = Hospital Anxiety and Depression Scale; SSM = Spinal Stenosis Measure

10.1371/journal.pone.0207126.t004

###### PROCESS: Estimated coefficients and their 95% confidence intervals, p-values, and shrinked coefficients for the SSM function score.

The shrinkage factor was 0.60.
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  MCID in SSM function                                                                     Coefficients = log odds ratios   Lower bound of 95% CI   Upper bound of 95% CI   p-value   Shrinked coefficients
  ---------------------------------------------------------------------------------------- -------------------------------- ----------------------- ----------------------- --------- -----------------------
  (Intercept)                                                                              -1.054                           -3.692                  1.584                   0.432     -0.633
  Age                                                                                      -0.603                           -1.233                  0.028                   0.061     -0.362
  Gender                                                                                   -0.002                           -0.670                  0.665                   0.994     -0.001
  Body mass index                                                                          -0.957                           -1.634                  -0.281                  0.006     -0.574
  Current smoker                                                                           0.467                            -0.370                  1.304                   0.273     0.280
  Civil status                                                                             0.592                            -0.133                  1.316                   0.109     0.355
  Formal education                                                                         0.113                            -0.607                  0.834                   0.757     0.068
  Coxarthrosis or gonarthrosis                                                             -0.711                           -1.364                  -0.058                  0.033     -0.427
  Coronary heart disease or heart insufficiency                                            -0.742                           -1.834                  0.351                   0.182     -0.445
  Asthma or COPD                                                                           -0.722                           -1.769                  0.326                   0.176     -0.433
  Parkinson's disease or peripheral neuropathy                                             -1.103                           -2.930                  0.725                   0.234     -0.662
  Walking ability                                                                          0.108                            -0.676                  0.892                   0.786     0.065
  Low back pain                                                                            -1.127                           -2.111                  -0.142                  0.025     -0.676
  Duration of symptoms                                                                     -0.046                           -0.672                  0.580                   0.885     -0.028
  Preoperative analgesic use within 3 months before baseline                               -0.366                           -1.168                  0.435                   0.369     -0.220
  Previous lumbar surgery                                                                  -0.987                           -1.951                  -0.022                  0.045     -0.592
  Number of decompressed levels                                                            -0.377                           -1.001                  0.247                   0.235     -0.226
  Antero-posterior diameter of dural sac (APD) \>6 mm or cross sectional area \>70 mm^2^   -0.571                           -1.322                  0.180                   0.136     -0.343
  Depression (on HADS depression scale)                                                    -0.552                           -1.350                  0.247                   0.175     -0.331
  Quality of life (EQ5D-3L scale)                                                          0.010                            -0.004                  0.025                   0.169     0.006
  Baseline SSM symptoms score                                                              -0.239                           -0.834                  0.357                   0.431     -0.143
  Baseline SSM function score                                                              2.038                            1.312                   2.764                   \<0.001   1.223

CI = confidence interval; COPD = chronic obstructive pulmonary disease; HADS = Hospital Anxiety and Depression Scale; SSM = Spinal Stenosis Measure

Discriminative ability of PROCESS, calibration and validation {#sec024}
-------------------------------------------------------------

In the derivation subsample, the discriminative ability as measured with the AUC of the PPF was 0.64 (95% CI 0.57 to 0.71) for the MCID in SSM symptoms score after shrinkage. The AUC was 0.62 (0.52 to 0.72) in the validation subsample. The corresponding values were 0.71 (0.64 to 0.77) in the derivation subsample and 0.70 (0.60 to 0.79) in the validation subsample for the MCID in SSM function score.

The corresponding ROC curves are displayed in [Fig 2](#pone.0207126.g002){ref-type="fig"} by applying the PPF with shrinked coefficients to the ten derivation (black lines) and the ten validation (grey lines) subsamples resulting from the multiple imputation. The left panel shows the MCID in SSM symptoms score, and the right panel shows MCID in SSM function score.

![Receiver operating characteristic curves for MCID in SSM symptoms score and SSM function score.\
· Black lines show results from ten imputed derivation subsamples, grey lines show results from ten imputed validation subsamples. The discriminative ability of the PPF was 0.64 (derivation = black lines) and 0.62 (validation = grey lines) for SSM symptoms score (left panel). The corresponding values were 0.71 and 0.70 for SSM function score as outcome (right panel). MCID = meaningful clinically important difference; SSM = Spinal Stenosis Measure.](pone.0207126.g002){#pone.0207126.g002}

The calibration plots in [Fig 3](#pone.0207126.g003){ref-type="fig"} show that there was good overall calibration of the PPFs when probabilities for MCID were displayed against bins of observed probabilities for MCID. The upper panels show results for SSM symptoms score, and the lower panels show results for SSM function score.

![Calibration plots of observed versus predicted probabilities for MCID in SSM symptoms score and SSM function score.\
The left panel shows results from the derivation subsample, and the right panel shows results from the validation subsample. Overall, there was good calibration of the PPF when probabilities for MCID were displayed against bins of observed probabilities for MCID, shown in upper panels for SSM symptoms score and lower panels for SSM function score. MCID = meaningful clinically important difference; SSM = Spinal Stenosis Measure; MI = multiple imputation.](pone.0207126.g003){#pone.0207126.g003}

The information whether fusion was added or not to decompression surgery was entered as an additional variable to the PPF. The resulting AUC of the PPF in the derivation subsample was 0.64 (95% CI 0.57 to 0.71) for the MCID in SSM symptoms score after shrinkage and 0.62 (0.52 to 0.72) in the validation subsample. The corresponding values for the MCID in SSM function score were 0.71 (0.64 to 0.77) and 0.68 (0.59 to 0.77).

Specific patient scenarios {#sec025}
--------------------------

The estimated probability for MCID after surgery in SSM symptoms score was 81% in the favorable scenario (Scenario 1), and 9% in the unfavorable scenario (Scenario 2). For the MCID in SSM function score, the first scenario resulted in an estimated probability of success of 97%, while it was only 6% in the second scenario.

We demonstrate how these two scenarios lead to the aforementioned probabilities in [S1](#pone.0207126.s001){ref-type="supplementary-material"} and [S2](#pone.0207126.s002){ref-type="supplementary-material"} Tables. The probabilities of every other constellation of prognostic indicators can be calculated online at [www.evimed.ch/PROCESS](http://www.evimed.ch/PROCESS).

Discussion {#sec026}
==========

We derived and validated PROCESS in a population of 452 patients with lumbar spinal stenosis in order to estimate the probability of reaching a minimal clinically important difference (MCID) one year after baseline. The discriminative ability and calibration of the PPF for MCID in SSM function score was better than that for SSM symptoms score. Approximately two thirds of the patients benefitted from spinal surgery, however, preoperative prognostic indicators had a large impact on individual outcomes. High baseline pain or functional impairment levels were among the strongest indicators positively associated with MCID in symptoms or function. Depression, low back pain, and previous lumbar surgery were negatively associated. Estimated probabilities of MCID varied, and ranged from 6% to 97%.

The authors of current treatment guidelines identified limited evidence to recommend surgical treatment for patients with lumbar spinal stenosis \[[@pone.0207126.ref035]\], and did not address the importance of prognostic indicators in the treatment decision. Several prognostic indicators associated with clinically meaningful improvement were identified in a systematic review. These included better reported walking capacity, better self-rated health, and shorter symptom duration \[[@pone.0207126.ref022]\]. Indicators for an unfavorable outcome after surgery were cardiovascular comorbidity, low back pain, and higher outcome expectations \[[@pone.0207126.ref022]\]. The majority of the original studies included in the systematic review were of "low quality" and based on small patient samples, likely leading to overly simplified prediction models based on a single or a few prognostic indicators. More recently, several studies identified that a higher degree of baseline disability is associated with increased improvement of functional outcome \[[@pone.0207126.ref020], [@pone.0207126.ref036]--[@pone.0207126.ref038]\], while smoking \[[@pone.0207126.ref036], [@pone.0207126.ref039], [@pone.0207126.ref040]\] and psychiatric disease \[[@pone.0207126.ref020], [@pone.0207126.ref041]\] were associated with an unfavorable outcome. Athiviraham et al.\[[@pone.0207126.ref020]\] reported that higher BMI was associated with less functional improvement, while Pearson et al. \[[@pone.0207126.ref036]\] reported no difference in function between patients with BMI greater than or equal to 30 and those with a BMI below 30. A few recently published studies considered only a limited patient sample \[[@pone.0207126.ref020], [@pone.0207126.ref021], [@pone.0207126.ref037], [@pone.0207126.ref038]\] and did not investigate the influence of the indicators on established clinically meaningful improvement \[[@pone.0207126.ref020], [@pone.0207126.ref037], [@pone.0207126.ref038]\].

In PROCESS, all available prognostic indicators previously identified were simultaneously included. Given the serious problem of overfitting in the development of PPFs in a large database, we deliberately refrained from an additional selection of parameters collected in the LSOS database, as this would have resulted in optimism regarding the model's predictive performance in new patients \[[@pone.0207126.ref042]\]. To address optimism in PROCESS, shrinkage was applied to the regression coefficients and the final models were validated in a random sample of one third of patients previously withheld from the analysis.

The discriminative ability of PROCESS was not altered by the inclusion of the information whether fusion was added or not to decompression surgery.

This study has several strengths. The data were collected prospectively in multiple study centers, and the disease-specific questionnaires SSM symptoms score and SSM function score were used to measure pain and disability. We also applied advanced methodology to obtain a robust PPF using multiple imputation techniques and shrinkage. The performance of the PPF was measured with an unused validation portion of the data set.

A weakness of our study is the fact that the prognostic indicators "coronary heart disease or cardiac insufficiency", "asthma or COPD", and "Parkinson's disease or peripheral neuropathy" happened to have a low prevalence in our data set. Another weakness is that not all risk factors published by Aalto et al. \[[@pone.0207126.ref021], [@pone.0207126.ref022]\] and Athiviraham et al. \[[@pone.0207126.ref020]\] were collected in the LSOS study: we had no information on preoperative scoliosis (an exclusion criterion in our study when \>15°), income, or outcome expectations.

Our method provided clinicians with individualized estimates of success probability with respect to pain and functional improvement that was both easy to understand and simple to communicate to the patient.

Surgical treatment for patients with lumbar spinal stenosis is being performed with increasing frequency \[[@pone.0207126.ref043]\], leading to higher costs for the health care system. PROCESS is conditional on the individual pattern of preoperatively available prognostic indicators, and may be helpful for clinicians in counselling patients and in guiding the discussion on individual treatment decision in the era of personalized medicine.

Supporting information {#sec027}
======================
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